The BREEDIME Project Closing Symposium

Rwanda FDA hosted the BREEDIME Project Closing Symposium from 4th to 6th May 2026 at Rwanda FDA Headquarters in Kigali. The three-day event brought together consortium members, regulatory authorities, researchers, healthcare professionals, development partners, and stakeholders to reflect on the achievements and impact of the BREEDIME Project over the past 36 months.

Implemented under the leadership of Tanzania Medicines and Medical Devices Authority, the BREEDIME Project (Building Resilient Research Ethics, Diagnostics, and Medicines Regulatory Capacity during Routine and Public Health Emergency Periods) focused on strengthening clinical trials oversight, ethical review systems, and post-marketing surveillance of therapeutics, vaccines, diagnostics, and medical devices across partner institutions.

The project was developed in response to challenges affecting regulatory oversight and public health preparedness, particularly during emergencies. Through collaborative interventions and capacity-building initiatives, the project significantly contributed to improving patient safety, strengthening regulatory systems, and promoting resilient healthcare responses within participating countries.

As host of the symposium, Rwanda FDA provided a platform for participants to showcase the project’s achievements and impact, share lessons learned and best practices, strengthen partnerships, and promote sustainability and future collaborations in regulatory science and public health.

Furthermore, the symposium reinforced collaboration among project partners, regulatory authorities, healthcare professionals, and stakeholders while promoting sustainability and continued regulatory capacity development beyond the project lifecycle.

During this symposium, Rwanda FDA reaffirmed its commitment to strengthening regulatory excellence, advancing public health systems, and promoting international collaboration in healthcare innovation, resilience, and patient safety.